急性心衰治疗若干进展PPT课件
合集下载
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
急性心力衰竭药物治疗的 若干进展
2011.4
精品ppt
1
内容
• ASCEND-HF • DOSE
精品ppt
2
急性失代偿性心衰的预后
• Median length of hospital stay: 6 days • Hospital readmissionsHospital readmissions
Duke Heart Failure Research Pager: 970-0736
精品ppt
12
• Baylor • Duke • Harvard • Mayo Clinic • Minnesota • Montreal • Morehouse • Utah • Vermont
NHLBI Heart Failure Clinical Research Network
• 一种激素样物质，除扩张动脉和静脉外， 还可促进利钠利尿
• 降低患者左室充盈压和呼吸困难程度，缓 解症状
• FDA approved 2001
精品ppt
6
The Effects of Nesiritide on Neurohormones
精品ppt
7
The Hospitalized Patient
Severe Symptomatic Fluid Overload
I IIa IIb III
In patients with evidence of severely symptomatic fluid overload in the absence of systemic hypotension, vasodilators such as intravenous nitroglycerin, nitroprusside or neseritide can be beneficial when added to diuretics and/or in those who do not respond to diuretics alone.
肾功能恶化的定义：SCr>0.5 mg/dL.
精品ppt
Circulation. 2005;111:1487-1491 10
Mortality Within 30 Days of Treatment Associated With Nesiritide or Control Therapy With Overall Risk Ratio Calculated by Mantel-Haenszel Test Using a Fixed-Effects Model.
Rev Cardiovasc Med. 2002;3(suppl 4)
精Ar品chppInttern Med. 2002;162Intern Med. 2002;162
3
Acute heart failure with systolic dysfunction
Furosemide+/- Vasodilator
––20% at 30 days20% at 30 days ––50% at 6 months50% at 6 months • MortalityMortality ––11.6% at 30 days11.6% at 30 days ––33.1% at 12 months ––50% at 5 years50% at 5 years
• ADHF治疗新药乏善可陈
• 在不同医院和不同医生之间利尿剂的应用剂量和 应用方式均大相径庭，缺乏安全性和有效性的高 质量研究
• 终于有些进展
✓ ASCEND-HF（AHA 2010) ✓ DOSE最新结果（N Engl J Med 3月3号在线）
精品ppt
5
• 奈西立肽(Nesiritide，人类BNP) –
SBP>100 mmHg
SBP 85-100 mmHg
SBP < 85 mmHg
Vasodilator (NTG,SPN,BNP)
Vasodilator and/or inotropic (dobutamine, PDEI or levosimendan)
inotropic and/or Dopamine>5ug/kg/min
Good response: Oral therapy ACEI……
No response: Reconsider mechanistic therapy inotropic agents
精品ppt
4
ESC2005急性心衰诊断和治疗指南
ADHF的药物治疗终于取得了一些进展
• 在过去30年中，急性失代偿性心衰（ADHF）的 药物治疗几乎没有进展
荟萃3个小规模 试验： NSGET VMAC PROACTION
Copyright restrictions may apply.
精品ppt
11
Sackner-Bernstein, J. D. et al. JAMA 2005;293:1900-1905
ASCEND-HF
奈西立肽治疗失代偿性心衰患者 临床疗效的短期研究
ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008
精品ppt
9
5个研究的荟萃分析：奈西立肽对肾功能影响
wenku.baidu.com
study
311 325 326 VMAC Precedent Totals
New
A Report of the ACCF/ AHA Task精F品oprpcte on Practice Guidelines
8
• BNP可用于治疗急性心衰，患者的体征为肺充血/水肿， BP > 90mmHg
• 静注BNP时，其输注速率从0.015到0.03 ug/kg/min均可， 无论开始是否进行负荷推注（2ug/kg）。不推荐和其他静 注血管扩张剂联用
Control, n/N (%) Nesiritide, n/N (%)
4/29 (14) 2/42 (5)
9/102 (9) 45/216 (21)
9/83 (11) 69/472 (15)
15/74 (20) 15/85 (18) 36/203 (18) 74/273 (27) 29/162 (18) 169/797 (21)
2011.4
精品ppt
1
内容
• ASCEND-HF • DOSE
精品ppt
2
急性失代偿性心衰的预后
• Median length of hospital stay: 6 days • Hospital readmissionsHospital readmissions
Duke Heart Failure Research Pager: 970-0736
精品ppt
12
• Baylor • Duke • Harvard • Mayo Clinic • Minnesota • Montreal • Morehouse • Utah • Vermont
NHLBI Heart Failure Clinical Research Network
• 一种激素样物质，除扩张动脉和静脉外， 还可促进利钠利尿
• 降低患者左室充盈压和呼吸困难程度，缓 解症状
• FDA approved 2001
精品ppt
6
The Effects of Nesiritide on Neurohormones
精品ppt
7
The Hospitalized Patient
Severe Symptomatic Fluid Overload
I IIa IIb III
In patients with evidence of severely symptomatic fluid overload in the absence of systemic hypotension, vasodilators such as intravenous nitroglycerin, nitroprusside or neseritide can be beneficial when added to diuretics and/or in those who do not respond to diuretics alone.
肾功能恶化的定义：SCr>0.5 mg/dL.
精品ppt
Circulation. 2005;111:1487-1491 10
Mortality Within 30 Days of Treatment Associated With Nesiritide or Control Therapy With Overall Risk Ratio Calculated by Mantel-Haenszel Test Using a Fixed-Effects Model.
Rev Cardiovasc Med. 2002;3(suppl 4)
精Ar品chppInttern Med. 2002;162Intern Med. 2002;162
3
Acute heart failure with systolic dysfunction
Furosemide+/- Vasodilator
––20% at 30 days20% at 30 days ––50% at 6 months50% at 6 months • MortalityMortality ––11.6% at 30 days11.6% at 30 days ––33.1% at 12 months ––50% at 5 years50% at 5 years
• ADHF治疗新药乏善可陈
• 在不同医院和不同医生之间利尿剂的应用剂量和 应用方式均大相径庭，缺乏安全性和有效性的高 质量研究
• 终于有些进展
✓ ASCEND-HF（AHA 2010) ✓ DOSE最新结果（N Engl J Med 3月3号在线）
精品ppt
5
• 奈西立肽(Nesiritide，人类BNP) –
SBP>100 mmHg
SBP 85-100 mmHg
SBP < 85 mmHg
Vasodilator (NTG,SPN,BNP)
Vasodilator and/or inotropic (dobutamine, PDEI or levosimendan)
inotropic and/or Dopamine>5ug/kg/min
Good response: Oral therapy ACEI……
No response: Reconsider mechanistic therapy inotropic agents
精品ppt
4
ESC2005急性心衰诊断和治疗指南
ADHF的药物治疗终于取得了一些进展
• 在过去30年中，急性失代偿性心衰（ADHF）的 药物治疗几乎没有进展
荟萃3个小规模 试验： NSGET VMAC PROACTION
Copyright restrictions may apply.
精品ppt
11
Sackner-Bernstein, J. D. et al. JAMA 2005;293:1900-1905
ASCEND-HF
奈西立肽治疗失代偿性心衰患者 临床疗效的短期研究
ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008
精品ppt
9
5个研究的荟萃分析：奈西立肽对肾功能影响
wenku.baidu.com
study
311 325 326 VMAC Precedent Totals
New
A Report of the ACCF/ AHA Task精F品oprpcte on Practice Guidelines
8
• BNP可用于治疗急性心衰，患者的体征为肺充血/水肿， BP > 90mmHg
• 静注BNP时，其输注速率从0.015到0.03 ug/kg/min均可， 无论开始是否进行负荷推注（2ug/kg）。不推荐和其他静 注血管扩张剂联用
Control, n/N (%) Nesiritide, n/N (%)
4/29 (14) 2/42 (5)
9/102 (9) 45/216 (21)
9/83 (11) 69/472 (15)
15/74 (20) 15/85 (18) 36/203 (18) 74/273 (27) 29/162 (18) 169/797 (21)